Get the app Watchlists Portfolios Alerts Sign in Get started

ABIVAX Société Anonyme ABVX

Full chart Compare

Set alert

88.71 USD +3.80 (+4.48%)

At closeNov 3, 2026, 7:36 PM EST

88.31 -0.40 -0.45%

After hours · Nov 3, 7:36 PM ET

85.26 Day range 90.12

72.50 52-week range 145.31

YTD: -34.22%
1 year: -10.26%

Discussion (3)

Tim F ABVX Jun 5, 2026 5 months ago #1

What a shit show that was. Beat the living hell outta it and then buy it back hand over fist…what?

Tim F ABVX Feb 3, 2026 9 months ago #2

Somebody wants this pharma company

Member ABVX Dec 11, 2025 10 months ago #3

Abvx/Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
Terry Chrisomalis
Summary

Abivax SA (ABVX) retains a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ulcerative colitis.
Upcoming catalysts include 44-week maintenance data from ABTECT trials in Q2 2026 and potential NDA/MAA filings in H2 2026, contingent on positive results.
Obefazimod's oral dosing, favorable safety, and novel miR-124 mechanism position ABVX to penetrate 2nd/3rd-line UC therapy, move to 1st-line and expand into Crohn's disease.
Recent $700M+ capital raise extends cash runway into Q4 2027, supporting ongoing pivotal trials and strategic expansion opportunitie